We examined interferon (IFN)-γ production from splenocytes isolated from these models and found that VVL-12 treatment was able to modestly induce IFN-γ production from ex vivo re-stimulated splenocytes at 3 or 8 days after VV therapy, but significantly enhanced ex vivo IFN-γ production by splenocytes stimulated with mitomycin C-treated CMT64 and LLC lung cancer cells harvested at 15 days post-treatment. The gene discussed is IFNG; the disease is lung carcinoma.